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Abstract
Background: Increasing the use of generic drugs may reduce the growing healthcare spending. Nevertheless, in
Japan, the generic drug market share remains low compared to that of European countries and the United States,
mainly because of the general distrust of generic drugs. To address this problem, we retrospectively evaluated the
efficacy and safety of the long-term use of generic pravastatin sodium in a study from January 2008 to December 2011.
Methods: Patients receiving generic pravastatin sodium for ≥15 months were defined as long-term users and were
included in the study, totaling 595 out of 1337 patients. Efficacy assessment was based on the total cholesterol
(TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) plasma levels. Safety
assessment was based on the aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine phosphokinase
(CPK), gamma-glutamyl transferase (γ-GTP), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), total-bilirubin
(T-Bil), blood urea nitrogen (BUN), serum creatinine (Scr), and hemoglobin A1c (HbA1c) plasma levels. The patients’
reasons for discontinuing generic pravastatin sodium were obtained from the electronic medical records.
Results & discussion: No significant difference in the laboratory data was observed between short-term and
long-term users, except for significantly lower ALT levels in the long-term users than in the short-term users. No liver
dysfunction was observed. Although 37 patients discontinued the study possibly owing to drug-related adverse events,
we considered these events unrelated to generic pravastatin sodium.
Conclusions: This study shows that the long-term use of generic pravastatin sodium is effective and safe, and may
help dispel the concerns about generic drugs.
Keywords: Pravastatin sodium, Generic drugs, Long-term use
Background
Increasing the use of generic instead of branded drugs is
desirable since it contributes to reducing healthcare
spending [1]. Although the generic drugs’ penetration
rates are approximately 50 % or more in Europe and the
United States, according to an aggregated value based on
a drug price survey conducted in September 2013, they
are 46.9 % in Japan, and are currently still low [2, 3]. To
address this situation, the Japanese Ministry of Health,
Labour and Welfare has set a goal to increase the volume
share of generic drugs to 60 % or more by the fiscal year
of 2018. Promotion of the use of generics also plays a large
role in the medical economy [4].
One of the reasons for the persistently low penetration
rate of generic drugs is the distrust of doctors and pa-
tients because less information on their efficacy and
safety is available than that for branded drugs [5]. To ad-
dress this issue, it is important not only to ensure the
biological and therapeutic equivalence of generic drugs
to those of branded drugs, but also to clinically assess
their efficacy and safety.
When we switched from branded to generic prava-
statin sodium tablets at our hospital, we assessed the
clinical efficacy and safety of the generic version on the
* Correspondence: Suzuki.masanori@kameda.jp
1Department of Pharmacy, Kameda General Hospital, 929 Higashi-cho,
Kamogawa-City 296-8602Chiba, Japan
Full list of author information is available at the end of the article
© 2015 Suzuki et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Suzuki et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:1 
DOI 10.1186/s40780-015-0033-4
basis of laboratory data and reported our findings [6]. In
this study, which included all 1337 patients who switched
to the generic pravastatin sodium tablet Maibastan® (Towa
Pharmaceutical, Co., Ltd.), we demonstrated that Maiba-
stan®’s clinical efficacy and safety were comparable to
those of the branded Mevalotin® tablet (Daiichi Sankyo
Co., Ltd.). However, since the study period was 6 months
and the long-term use of Mevalotin® was defined as
15 months or longer [6], the impact of Maibastan®’s long-
term use on clinical efficacy and safety remains unknown.
Moreover, although several clinical studies have compared
and analyzed the efficacy and safety of branded and gen-
eric drugs in patients switching from branded to generic
drugs, only few have investigated the clinical efficacy and
safety of the long-term use of the latter [7–9]. Thus, in the
present study, the duration of long-term use was defined
as 15 months or longer [10], and the study period was ex-
tended to last from January 1, 2008 to December 31, 2011.
All 1337 patients who had switched to Maibastan® in the
previous study were followed up, and a retrospective ob-
servational study using information from electronic med-
ical records to assess Maibastan®’s long-term use clinical
efficacy and safety was conducted.
Methods
Study period




The present study included all 1337 patients who had
switched from branded pravastatin sodium (Mevalotin®
tablet) to a generic version (Maibastan® tablet) between
January 1, 2008, and March 31, 2009. These patients
were classified into 6 different groups: long-term contin-
ued use group, treatment discontinuation group (long-
term), treatment discontinuation group (short-term),
drug-change group, dose-adjustment group, and con-
comitant drug-change group (Fig. 1). Definition of the
long-term treatment period was defined as 15 months or
longer of treatment according to a clinical study on the
long-term use of Mevalotin® [10].
Exclusion criteria
Patients for whom no efficacy and safety laboratory as-
sessment data were obtained during the short- and long-
term treatment periods were excluded from the study [5.
Assessment items, 2)].
Assessment items
1) The number of the target patients, male-to-female
ratio, mean age, and mean duration of orally admin-
istered Maibastan® tablets
Fig. 1 Overview of each treatment group and the study period. Short-term treatment period: From the day of substitution to March 31, 2009.
Long-term treatment period: From July 1 to December 31, 2011. Long-term continued use group: Patients who continued the treatment on and
after December 31, 2011. Treatment discontinuation group (long-term): Patients who discontinued the treatment between July 1 and December 31,
2011. Treatment discontinuation group (short-term): Patients who discontinued the treatment on or before July 1, 2011. Drug-change group: Patients
for whom the generic drug was replaced by another drug after substitution. Dose-adjustment group: Patients for whom the dose of the generic drug
was adjusted after substitution. Concomitant drug-change group: Patients whose concomitant drugs were switched after substitution. Long-term use
group: A group consisting of the long-term continued use group and the treatment discontinuation group (long-term). Discontinuation/change group:
A group consisting of the treatment discontinuation (short-term), drug-change, dose-adjustment, and concomitant drug-change group
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2) Efficacy and safety assessment based on laboratory
data
 Efficacy assessment
In the long-term use group, the results of the first la-
boratory test during the short-term treatment period
(from the day of substitution to March 31, 2009) were
compared with the results of the latest laboratory test
during the long-term treatment period (from July 1 to
December 31, 2011) (Fig. 2). The efficacy of the long-term
use of Maibastan® tablets was assessed by comparing the
following laboratory data: total cholesterol (TC), triglycer-
ide (TG), high-density lipoprotein cholesterol (HDL-C),
and low-density lipoprotein cholesterol (LDL-C).
 Safety assessment
In the long-term use group, the results of the first la-
boratory test during the short-term treatment period
(from the day of substitution to March 31, 2009) were
compared with those of the last laboratory test during
the long-term treatment period (from July 1 to Decem-
ber 31, 2011) (Fig. 2). The safety of Maibastan® tablets’
long-term use was assessed by comparing the following
laboratory data: aspartate aminotransferase (AST), ala-
nine aminotransferase (ALT), creatine phosphokinase
(CPK), gamma-glutamyl transferase (γ-GTP), alkaline
phosphatase (ALP), lactate dehydrogenase (LDH), total
bilirubin (T-Bil), blood urea nitrogen (BUN), serum cre-
atinine (Scr), and hemoglobin A1c (HbA1c).
3) Safety assessment based on the reasons for drug
discontinuation and changes
To assess the safety of Maibastan®, we reviewed the
medical records to identify the reasons underlying all
Maibastan® discontinuation and replacement cases and
compared the cases of adverse reactions to Maibastan®
with those reported for Mevalotin®. In the event of adverse
reactions that had not been reported for Mevalotin® or of
death, the patient data were reviewed to investigate a
causal relationship with orally administered Maibastan®.
The Common Terminology Criteria for Adverse Events
version 4.0, Japan Clinical Oncology Group version
(CTCAE, v4.0-JCOG), were used for grading of adverse
reactions for the safety assessment.
Analytical methods
Student’s t-test was used for intergroup comparison of
the laboratory data. The statistical significance level was
set at p < 0.05.
The study protocol was approved by the Clinical Study
Screening Committee at Kameda General Hospital.
Results
1) Sex and age of the target patients and treatment
duration of orally administered Maibastan® tablets
Of the 1337 patients who had switched from Mevalotin®
to Maibastan® tablets between January 1, 2008, and March
31, 2009, 595 patients continued receiving Maibastan® for
approximately 177 weeks, whereas the remaining 742
patients discontinued or changed their treatment for un-
defined reasons. The long-term use group consisted of 556
and 39 patients in the long-term continued use and treat-
ment discontinuation (long-term) group, respectively
(Table 1). The discontinuation/change group consisted
of 278, 329, 98, and 37 patients in the treatment discon-
tinuation (short-term), drug-change, dose-adjustment,
and concomitant drug-change group, respectively (Table
2). The efficacy and safety assessment based on labora-
tory data included the 595 patients in the long-term use
group, while the safety assessment based on the reasons
for discontinuation and drug change included 781
patients, i.e., 742 and 39 patients in the discontinuation/
change and treatment discontinuation (long-term) group,
respectively. No apparent difference was observed in the
male-to-female ratio and mean age between the target
patients.
2) Assessment of efficacy and safety based on
laboratory data
 Efficacy assessment
Fig. 2 Comparison of laboratory data between the treatment groups
Suzuki et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:1 Page 3 of 9
In the long-term continued use group, no significant
difference was observed in laboratory parameters be-
tween the Maibastan® tablets short- and long-term use
groups (Table 3) and in those of the treatment discon-
tinuation group (long-term) (Table 4).
 Safety assessment
Although in the long-term continued use group, a sig-
nificant decrease in ALT levels (p = 0.02) was observed
between the short- and long-term use of Maibastan® tablets,
no significant difference was observed in any of the other
laboratory parameters (Table 3). Moreover, no significant
difference in laboratory parameters was observed in the
treatment discontinuation group (long-term) (Table 4).
3) Safety assessment based on the reasons for drug
discontinuation and change
Among the 39 patients in the treatment discontinu-
ation group (long-term), the reasons for discontinuation
were not clearly indicated in the medical records of 28
patients. In five patients, treatment was discontinued
because of transfer to another hospital and because of
death, pregnancy, poor nutritional status, and advanced
age preventing chronic treatment in 3, 1, 1, and 1 pa-
tient(s), respectively.
Among the 278 patients in the treatment discontinu-
ation group (short-term), the reasons for discontinuation
were not clearly indicated in the medical records of 141
patients. In 62 patients, treatment was discontinued be-
cause of transfer to another hospital, and in 33, 21, 13,
3, 3, and 2 patients, because of death, adverse reactions,
decreased LDL-C levels, poor nutritional status, patient’s
own request, and old age preventing chronic treatment,
respectively. Among the 21 patients who discontinued
treatment because of adverse reactions, eight patients
presented symptoms suggestive of rhabdomyolysis, such
as increased CPK levels and myalgia.
Among the 329 patients in the drug-change group, the
reasons for drug change were not clearly indicated in
the medical records of 187 patients. Maibastan® was re-
placed by other drugs because of poor LDL-C control in
116 patients (Crestor® [AstraZeneca, Inc.; 61 patients],
Lipitor® [Astellas Pharma, Inc.; 54 patients], and Bezatol®
[Kissei Pharmaceutical Co., Ltd.; 1 patient]) and because
of poor TG control in 9 patients (Crestor®, Lipitor®,
Bezatol®, and Lipidil® [Kaken Pharmaceutical Co., Ltd.; 2
patients each] and Zetia® [Bayer AG; 1 patient]). More-
over, 1 patient switched from Maibastan® to another
drug (Bezatol®) because of favorable LDL-C control.
Adverse reactions caused all 16 patients to switch from
the generic drug to other drugs (Lipitor® tablet in 9
patients, Crestor® and Zetia® tablet in 3 patients each,
and Epadel® capsule [Mochida Pharmaceutical Co., Ltd.]
in 1 patient). Nine of the patients presented symptoms
suggestive of rhabdomyolysis, such as increased CPK
levels, myalgia, and weakness.
Among the 98 patients in the dose-adjustment group,
the reasons for drug change were not clearly indicated in





Patients (N) 556 39
Men/women (N) 224/332 18/21
Mean age (years) 68.8 ± 10.9 73.8 ± 11.8
Mean treatment
duration (weeks)
177 ± 3.61 158 ± 3.54
Table 2 Patient characteristics. (2) Discontinuation/change group
Concomitant drug-change Drug-change Dose-adjustment Discontinuation (short-term)
Patients (N) 37 329 98 278
Men/women (N) 24/13 150/179 44/54 103/175
Mean age (years) 66.7 66.8 68.1 70.9
Mean treatment duration (weeks) 144 ± 3.50 66.6 ± 3.53 143 ± 3.71 63.8 ± 4.00
Age (years) Duration (weeks)
Mean S.D. Mean S.D.
Long-term continued use 68.8 10.9 177 3.61
Discontinuation (long-term) 73.8 11.8 158 3.54
Concomitant drug-change 66.7 11.0 144 3.50
Drug-change 66.8 11.1 66.6 3.53
Dose-adjustment 68.1 11.2 143 3.71
Discontinuation (short-term) 70.9 12.5 63.8 4.00
Standard deviation, S.D
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the medical records of 33 patients. In 37 patients, the
doses of Maibastan® tablet were reduced because of favor-
able LDL-C control, and in 27 and 1 patient(s), because of
poor LDL-C and TG control, respectively.
Among the 37 patients in the concomitant drug-
change group, the reasons for drug change were not
clearly indicated in the medical records of 17 patients.
In 11 patients, other drugs were added as treatment
because of poor LDL-C control (Zetia® tablet in 10 pa-
tients and Bezatol® tablet in 1 patient) and poor TG con-
trol in 9 patients (Zetia® and Bezatol® tablet in 3 patients
each, Lipidil® tablet in 2 patients, and Perycit® tablet
[Sanwa Kagaku Kenkyusho Co., Ltd.] in 1 patient).
During the current study period, treatment was dis-
continued or changed because of adverse reactions in a
total of 37 patients. Among them, abnormal laboratory
Table 3 Assessment of efficacy and safety based on laboratory data (the long-term continual use group)
Short-term treatment Long-term treatment
Plasma parameter Mean ± S.D. N Mean ± S.D. N p-value
TC 195 ± 25.0 407 196 ± 28.5 417 0.42
TG 129 ± 76.8 405 123 ± 65.5 449 0.16
HDL-C 60.8 ± 15.6 388 61.9 ± 16.6 437 0.32
LDL-C 109 ± 20.1 239 112 ± 24.0 246 0.06
AST 24.2 ± 12.2 419 23.2 ± 9.29 473 0.19
ALT 23.1 ± 21.6 418 20.4 ± 11.3 473 0.02
CPK 112 ± 86.5 358 108 ± 67.9 395 0.51
γ-GTP 35.3 ± 52.4 324 33.0 ± 35.5 385 0.50
ALP 236 ± 72.1 266 245 ± 81.8 286 0.18
T-Bil 0.66 ± 0.25 242 0.67 ± 0.27 303 0.91
LDH 198 ± 37.4 372 196 ± 39.1 417 0.48
BUN 17.0 ± 8.78 384 17.6 ± 8.39 461 0.27
Scr 0.87 ± 0.55 413 0.91 ± 0.74 478 0.40
HbA1c 6.26 ± 0.83 308 6.24 ± 0.88 341 0.87
Total plasma cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-C; low-density lipoprotein cholesterol, LDL-C; aspartate aminotransferase,
AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; lactate dehydrogenase, LDH; total
bilirubin, T-Bil; blood urea nitrogen, BUN; serum creatinine, Scr; hemoglobin A1c, HbA1c; standard deviation, S.D
Table 4 Assessment of efficacy and safety based on laboratory data (the treatment discontinuation group)
Short-term treatment Long-term treatment
Plasma parameter Mean ± S.D. N Mean ± S.D. N p-value
TC 188 ± 31.2 31 179 ± 39.4 16 0.38
TG 117 ± 51.1 30 109 ± 50.0 17 0.62
HDL-C 61.4 ± 22.6 28 59 ± 18.5 17 0.71
LDL-C 102 ± 19.2 20 96.6 ± 26.4 11 0.56
AST 20.7 ± 7.15 33 19.6 ± 7.29 26 0.57
ALT 17.6 ± 9.37 33 15.3 ± 7.74 26 0.32
CPK 81.9 ± 40.1 30 83.6 ± 44.1 19 0.89
γ-GTP 31.7 ± 37.4 26 39.1 ± 42.9 21 0.53
ALP 237 ± 69.3 23 285 ± 134 21 0.16
T-Bil 0.76 ± 0.48 24 0.57 ± 0.25 20 0.10
LDH 190 ± 35.1 30 182 ± 56.0 22 0.54
BUN 16.6 ± 5.46 35 19.3 ± 9.33 27 0.19
Scr 0.85 ± 0.28 35 0.91 ± 0.41 27 0.52
HbA1c 6.32 ± 0.95 22 6.15 ± 0.4 11 0.47
Total plasma cholesterol, TC; triglyceride, TG; high-density lipoprotein cholesterol, HDL-C; low-density lipoprotein cholesterol, LDL-C; aspartate aminotransferase,
AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline phosphatase, ALP; lactate dehydrogenase, LDH; total
bilirubin, T-Bil; blood urea nitrogen, BUN; serum creatinine, Scr; hemoglobin A1c, HbA1c; standard deviation, S.D
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data were observed in 13 patients, and 24 patients re-
ported adverse reactions. The adverse reactions deter-
mined by abnormal laboratory data in the 13 patients
were increased CPK, AST and ALT, ALP and γ-GTP and
decreased Hb levels in 9, 1, 1, and 1 patient(s), respect-
ively. Thrombocytopenia was observed in 1 patient
(Table 5).
Moreover, CTCAE grade II or higher adverse reactions
were observed in 2 patients with increased CPK levels
(grade II and IV) and in 1 patient each with increased γ-
GTP levels, decreased Hb levels, and thrombocytopenia
(all were grade II). The adverse reactions reported by 24
patients were myalgia in 7, rash in 6, discomfort in 3,
and myospasm in 2 patients, as well as arrhythmia,
numbness, malaise, nausea, weakness, and vertigo in 1
patient each. Of these reported adverse reactions,
muscle-associated adverse reactions suggestive of
rhabdomyolysis (increased CPK levels, myalgia, myos-
pasm, numbness, malaise, and weakness) accounted for
a large proportion of the patients (21 out of 37).
Comparison with the reported adverse reactions to or-
ally administered Mevalotin® revealed no apparent in-
crease in the incidence of adverse reactions to orally
administered Maibastan® tablets (Table 6). Moreover, 3
cases of discomfort and 1 case of arrhythmia, which
were not reported as adverse reactions to Mevalotin®,
were examined in detail using the information in the
electronic medical records (e.g., past history and con-
comitant drugs).
Case 1 is a 48-year-old man treated for dyslipidemia
on an outpatient basis. Ten months after switching to
Maibastan® tablet, he complained of discomfort, and
drug treatment was discontinued. The patient’s discom-
fort was related to the use of Maibastan® tablet together
with 2 drugs prescribed for sinusitis at another hospital
(unspecified). The other concomitant drugs used were
Bayaspirin® tablet (Bayer AG), Juvela® capsule (Eisai Co.,
Ltd.), and Foliamin® tablet (Takeda Pharmaceutical Co.,
Ltd.). Discontinuation of all drugs relieved the patient’s
discomfort.
Case 2 is a 76-year-old man treated for chronic renal
failure, renal anemia, hypertension, prostatomegaly, and
dyslipidemia on an outpatient basis. Two months after
switching to Maibastan® tablet, he complained of dis-
comfort, and drug treatment was discontinued. Because
of discomfort, the patient discontinued the use of Urief®
(Daiichi Sankyo Co. Ltd.), Maibastan®, Tenormin® (Astra-
Zeneca, Inc.), and Myslee® tablet (AstraZeneca, Inc.) at
his own discretion. The patient’s discomfort was subse-
quently relieved. The use of the other concomitant
drugs, Adalat® (Bayer AG) and Blopress® tablet (Takeda
Pharmaceutical Co., Ltd.), was not discontinued.
Case 3 is an 88-year-old woman treated for
hypothyroidism and dyslipidemia on an outpatient basis.
Two months after switching to Maibastan® tablet, she
complained of discomfort, and drug treatment was dis-
continued. Because of discomfort, the patient discontin-
ued Maibastan® and Hachimi-jio-gan® extract tablet
(Kracie Pharma, Ltd.) at her own discretion. The pa-
tient’s discomfort was subsequently relieved. The use of
the other concomitant drug, Thyradin-S® tablet (Takeda
Pharmaceutical Co. Ltd.), was not discontinued.
Case 4 is a 66-year-old woman treated for diabetes mel-
litus, hypertension, and dyslipidemia on an outpatient
Table 5 Reports of adverse reactions determined by abnormal laboratory data
Age (years) Sex Treatment duration (weeks) Adverse reaction CTCAE Grade
70 Female 16 Increased CPK 200 IU/L I
66 Female 10 Increased CPK 219 IU/L I
67 Female 40 Increased CPK 189 IU/L I
68 Female 15 Increased CPK 200 IU/L I
78 Female 4 Increased CPK 2898 IU/L IV
52 Male 12 Increased CPK 321 IU/L I
67 Male 35 Increased CPK 762 IU/L I
36 Male 4 Increased CPK 404 IU/L I
40 Male 10 Increased CPK 815 IU/L II
69 Female 4 Increased AST 49 IU/L I
41 Male 32 Increased ALT 42 IU/L I
Increased ALP 376 IU/L I
Increased γ-GTP 194 IU/L II
65 Male 23 Decreased Hb 9.7 g/dL -
85 Female 15 Thrombocytopenia 65,000 /mL II
Aspartate aminotransferase, AST; alanine aminotransferase, ALT; creatine phosphokinase, CPK; gamma-glutamyl transferase, γGTP; alkaline phosphatase, ALP;
hemoglobin, Hb; The Common Terminology Criteria for Adverse Events, CTCAE
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basis. Twenty months after switching to Maibastan® tablet,
she complained of a racing pulse, and treatment was dis-
continued. This patient discontinued Maibastan® tablet at
her own discretion and her symptom was subsequently re-
lieved. The use of the concomitant drugs Olmetec® (Daii-
chi Sankyo Co., Ltd.) and Fastic® tablet (Mochida
Pharmaceutical Co., Ltd.) was not discontinued (Table 7).
Discussion
Efficacy and safety assessment based on laboratory data
included those of the patients in the long-term use group,
which consisted of 556 patients in the long-term contin-
ued use and 39 patients in the treatment discontinuation
(long-term) group. Regarding the efficacy in the long-term
continued use group, no statistically significant difference
was observed between the first TC, TG, HDL-C, and
LDL-C levels measured during the short-term use of
Maibastan® tablets and those of the last measured during
the long-term treatment period. Furthermore, no significant
difference between these parameters was observed in the
treatment discontinuation group (long-term). Thus, it was
assumed that the effects of the long-term use of Maibastan®
tablets were similar to those of Mevalotin® tablets.
Similarly, regarding the safety assessment in the long-
term continued use group, no statistically significant dif-
ference was observed between the first AST, ALT, CPK, γ-
GTP, ALP, LDH, T-Bil, BUN, Scr, and HbA1c levels mea-
sured during the short-term use of Maibastan® tablet
period and those of the last measurement during the
long-term treatment period, except for the ALT levels.
While the ALT levels were significantly lower in the
Maibastan® tablet long-term use group than those in the
short-term use group, the levels did not fluctuate through-
out the long-term treatment period. A recent report from
the Greek Atorvastatin and Coronary Heart Disease
Evaluation (GREACE) study indicated that the use of
statins in patients with a fatty liver improved liver function
and reduced cardiovascular events [11]. As for the reason
for the decreased ALT levels, the report also suggested
that the inhibitory action of Maibastan® against hepatic
3-methylglutaryl coenzyme A (HMG-CoA) reductase
Table 6 Comparison of adverse reactions reported for the
branded and generic drugs
Adverse reaction Case
(N)
Present study Package insert
Incidence (%) Incidence (%)
Increased CPK 9 0.67 Unknown
Myalgia 7 0.52 Unknown
Rash 6 0.45 0.1-1
Discomfort 3 0.22 No documentation
Myospasm 2 0.15 <0.1
Arrhythmia 1 0.07 No documentation
Increased ALP and γ-GTP 1 0.07 0.1–1
Numbness 1 0.07 <0.1
Malaise 1 0.07 <0.1
Nausea 1 0.07 <0.1
Increased AST and ALT 1 0.07 Unknown
Thrombocytopenia 1 0.07 Unknown
Anemia (decreased Hb) 1 0.07 Unknown
Weakness 1 0.07 Unknown
Vertigo 1 0.07 Unknown
Creatine phosphokinase, CPK; gamma-glutamyl transferase, γ-GTP; alkaline
phosphatase, ALP; aspartate aminotransferase, AST; alanine aminotransferase,
ALT; hemoglobin, Hb




Discomfort A 48-year-old man complained of discomfort after receiving Maibastan® for 10 months, and the treatment was discontinued. Before
symptom onset, the concomitant drugs had not been changed. Discontinuation of Maibastan® and the concomitant drugs* resulted
in symptom relief.
*Bayaspirin®, Juvela®, Foliamin®, Erythrocin®, and Mucodyne®
A 76-year-old man complained of discomfort after receiving Maibastan® for 2 months, and the treatment was discontinued. Before
symptom onset, the concomitant drugs* had not been changed. Discontinuation of Maibastan®, Urief®, Tenormin®, and Myslee®
resulted in symptom relief.
*Urief®, Tenormin®, Myslee®, Adalat®, and Blopress®
An 88-year-old woman complained of discomfort after receiving Maibastan® for 2 months, and drug treatment was changed to
Epadel®. Before symptom onset, the concomitant drugs* had not been changed. Discontinuation of Maibastan® and Hachimi-jio-gan®
resulted in symptom relief.
*Thyradin S® and Hachimi-jio-gan®
Arrhythmia A 66-year-old woman complained of the sensation of having a racing pulse after receiving Maibastan® for 20 months, and the
treatment was discontinued. Before symptom onset, the concomitant drugs* had not been changed. Discontinuation of Maibastan®
resulted in symptom relief.
*Olmetec® and Fastic®
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reduced stress, such as a fatty liver, affecting liver function.
A similar comparison of the laboratory parameter values
in the treatment discontinuation group showed no signifi-
cant differences.
For the safety assessment, review of the patients’ med-
ical records identified the reasons underlying all cases of
drug discontinuation and change during the current
study period. Detailed review of the medical records
containing no documented reasons revealed the absence
of patients’ complaints about symptoms suggestive of ad-
verse reactions, abnormal laboratory data during treat-
ment, or adverse events, such as death.
Next, to investigate the safety of the long-term use of
Maibastan® tablets, the medical records of patients who
had died or had adverse reactions were reviewed in detail.
Among all the 36 patients who had died, drug discontinu-
ation and change were suspected to be caused by primary
diseases, and it was assumed that there was no causal rela-
tionship with the oral administration of Maibastan® tablets.
In the drug discontinuation and change due to adverse
reactions cases, Maibastan® tablet was considered respon-
sible for each adverse reaction. Indeed, 21 out of the 37
cases showed muscle-associated symptoms suggestive of
rhabdomyolysis (increased CPK levels, myalgia, myospasm,
numbness, malaise, and weakness). However, these findings
were derived from pravastatin sodium preparations and
may be considered Maibastan® tablet-unrelated adverse
reactions. Moreover, the adverse reactions observed in 12
out of the 37 cases, which included rash, increased ALP
and γ-GTP levels, nausea, hepatopathy, thrombocytopenia,
decreased Hb levels, and vertigo, were also reported for the
branded drug (Mevalotin®), and no apparent increase in
their incidence was observed. Thus, these adverse reactions
may also be considered Maibastan® tablet-unrelated. Be-
cause discomfort (case 1, 2, and 3) and arrhythmia (case 4),
which were observed in the remaining 4 cases, had not
been reported in the adverse reaction reports for the
branded drug, we investigated whether these adverse reac-
tions were specific to Maibastan® tablet treatment. Al-
though discomfort was relieved in these 3 cases(case 1, 2,
and 3) after discontinuation of Maibastan® tablet, this
adverse reaction may not be specific to the tablet: the pa-
tients were taking several oral drugs and had comorbidities
associated with poor physical conditions, such as sinusitis,
renal anemia, and hypothyroidism. Although the symp-
tom(case 4) was relieved after discontinuation of Maiba-
stan® tablet only, it has been reported that arrhythmic
symptoms, such as extrasystole, are detected in approxi-
mately 3.8 % of healthy people, and that the incidence of
such symptoms is higher in patients with hypertension
[12, 13]. Because the patient of case 4 had concomitant
hypertension, it cannot be ruled out that the racing pulse
she experienced was caused by transient extrasystole.
Thus, this symptom may not be a Maibastan® tablet-
specific adverse reaction. According to the findings de-
scribed above, it is assumed that Maibastan® tablet may be
safely used for long-term treatment.
We previously conducted questionnaire surveys on
generic drugs among doctors, nurses, and pharmacists at
our hospital and found that several healthcare professionals
had concerns about the limited amount of information on
clinical efficacy and adverse reactions [14, 15]. Although
several studies have examined the efficacy and safety of
generic drugs, the number of studies focusing on individual
drugs and the amount of information provided by such
studies has not been sufficient to eliminate this concern.
Some studies have also assessed the efficacy and safety of
generic pravastatin sodium tablets. However, in several of
these studies, less than 100 cases were evaluated, and the
duration of generic drug treatment lasted for 3 months or
less; even the longest duration lasted 6 months at most
[16–19]. Drugs for the treatment of chronic diseases are
often orally administered for many years. Especially, for
dyslipidemia, strict long-term lipid control is necessary for
the primary and secondary prevention of cardiovascular
events. Thus, studies on the efficacy and safety of long-
term drug use are highly useful information sources. The
present study provides results on the efficacy and safety of
a generic drug based on the assessment of a sufficient
number of cases and sufficient treatment duration. The
proliferation of generic drugs is highly desired to reduce
healthcare spending. However, the major future tasks are
not only to ensure their bioequivalence with branded
drugs, but also to increase data provision on generic drug
efficacy and safety by conducting clinical studies. In these
tasks, pharmacists are essential since they are drug special-
ists. Therefore, pharmacists should be actively involved
through pharmacist-led clinical assessments of generic
drugs. The present study may have large clinical signifi-
cance for the efficacy and safety assessment of the long-
term use of generic drugs.
Conclusion
This study shows that the long-term use of generic prav-
astatin sodium is effective and safe, and may help dispel
the concerns about generic drugs.
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